Market Opportunity in Photodynamic Therapy (PDT)
•The SPIDER’s patented delivery system and platform combines therapeutic compound delivery with revolutionary tissue healing and infection mitigating technology to enable improved wound healing in a minimally invasive fashion.
•The SPIDER would be among the first platforms using PDT to treat and prevent infection of capsular joints.
•This application could springboard this technology to greater applications.
PDT
•Photodynamic therapy (PDT) has received clinical approval for use as a minimally-invasive therapeutic procedure, and it has been widely applied in the diagnosis and treatment of malignancies, including lung, esophageal, gastrointestinal, bladder, prostate, head & neck, and oral & skin cancer. Infection would be a new field.
•The global photodynamic therapy market was valued at ~US$ 3 Bn in 2018, and is anticipated to reach ~US$ 11.8 Bn by 2027.
•SPIDER offers both a platform for infection control and wound healing.
Phase One: Septic Arthritis Market
•Each year, 13-20K patients are diagnosed with septic arthritis, at a cost of more than $750 million. Knees are the most commonly affected, but hips and shoulders are commonly infected too.
•Current therapies often lead to further joint and tissue damage, are frequently unsuccessful, and joint replacement may still need to occur.
•Recent trials suggest a less invasive approach may be more successful.
•SPIDER offers a platform for such an approach.
Phase One Continued-Revenue
•Capsular Joint and large tissue infections: Orthopedic departments
•Typically 4th greatest revenue generator at hospitals
•Shift to more ambulatory setting
•Hospitals, medical groups
•With improved comfort of device, natural evolution of technology will be toward involvement of multidrug resistant organisms.
Phase Two: Resistant Bacteria
•The CDC estimated that the cost of antimicrobial resistance is $55 billion every year in the United States, $20 billion for health care and about $35 billion for loss of productivity.
•The CDC estimates nearly 2 million patients in the USA are affected by antibiotic resistant organisms.
•SPIDER would offer a means to irrigate infected tissues in a minimally invasive way while promoting wound healing by PDT.
The Opportunity- ground floor of a revolution in wound healing.
$750 million per year septic arthritis market
And potential to contribute to a $35 billion a year in lost productivity saving.
Phase Three: Other potential markets
•Rehabilitation:
•Osteoarthritis: Currently, no consensus on best, minimally invasive therapy, so SPIDER to offer opportunity to pursue a number of approaches.
•PRP infusion as outlined in protocol from Etulain et al Scientific Reports 2018 and Russo et al. PLOS one 2016.
•Saline or hypertonic saline or hyperosmolar sugar solution delivery. Eltawil et al. Osteroarthritis Cartilige 2015, Bradley Osteoarthritis 2003.
•Mesenchymal Stem Cell delivery. See Pers et al. Osteroarthritis and Cartilage 2015.
•Microfragmented adipose tissue (MFAT). See Mautner et al. Stem Cells Transl Med 2019.
•Wharton’s Jelly infusion.
•Post-infusion NIR and osteoarthritis preventative photobiomodulation. See Desmet et al. Photomedicine and Laser Surgery 2006 for delivery protocol.
•Infection Recovery:
•Hydrogen peroxide irrigation as outlined in Lu & Hansen J. Bone Joint Infection 2017
•Povidone-Iodine irrigation. See Ruder & Springer J. Bone Joint Infect 2017.
Emerging Stem Cell Opportunities
•Companies in Stem Cell & Regenerative Medicine – stemcellreferencestemcellreference
•10 Top Stem Cell Companies on the NASDAQ | INN (investingnews.com)
Emerging Stem Cell Opportunities
•Currently, most companies in the stem cell field are looking at their use in gene therapies for disease or drug manufacturing.
•GID Bio is currently investigating the harvesting of patients stromal and vascular cells in an FDA phase II trial for treatment of osteoarthritis.
•The SPIDER offers a delivery platform already patented for stem cell use.